Direct-To-Consumer Ads Are Misleading: Concise Statements of Effectiveness Should Be Required by Bohrer, Robert A.
Journal of Health Care Law and Policy 
Volume 22 Issue 2 Article 15 
Direct-To-Consumer Ads Are Misleading: Concise Statements of 
Effectiveness Should Be Required 
Robert A. Bohrer 
Follow this and additional works at: https://digitalcommons.law.umaryland.edu/jhclp 
Recommended Citation 
Robert A. Bohrer, Direct-To-Consumer Ads Are Misleading: Concise Statements of Effectiveness Should 
Be Required, 22 J. Health Care L. & Pol'y 209 (2020). 
Available at: https://digitalcommons.law.umaryland.edu/jhclp/vol22/iss2/15 
This Article is brought to you for free and open access by the Academic Journals at DigitalCommons@UM Carey 
Law. It has been accepted for inclusion in Journal of Health Care Law and Policy by an authorized editor of 
DigitalCommons@UM Carey Law. For more information, please contact smccarty@law.umaryland.edu. 
  
 
209 
DIRECT-TO-CONSUMER ADS ARE 
MISLEADING: CONCISE 
STATEMENTS OF EFFECTIVENESS 
SHOULD BE REQUIRED 
ROBERT A. BOHRER, J.D., LL.M. 
INTRODUCTION: THE PROBLEM WITH PHARMACEUTICAL ADVERTISING 
The issue of required disclaimers in direct-to-consumer (DTC) advertising 
of pharmaceuticals boiled to the surface in May 2019, when the Centers for 
Medicare and Medicaid Services (CMS) published a final rule requiring the 
disclosure of a drug’s price in DTC ads.1 The idea is not a new one––the 
American Medical Association (AMA) adopted a resolution recommending just 
such a required disclosure in June 2017.2 For a number of reasons, even if the 
proposal is implemented it may not have much effect.3 Consumers may see price 
as an indicator of effectiveness, just as a high-priced car is expected to be 
superior to a lower-priced car, and insurance coverage may reduce patients’ 
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 1. Centers for Medicare and Medicaid Services (CMS), Medicare and Medicaid Programs; 
Regulation To Require Drug Pricing Transparency, 83 Fed. Reg. 52,789 (proposed Oct. 18, 2018) (to be 
codified at 42 C.F.R. pt. 403) [herinafter CMS]. The CMS rule was struck down as violative of 
pharmaceutical companies’ commercial speech rights in Merck v.H.H.S.  385 F. Supp. 3d 81 (D. D.C. 
2019). The agency filed a notice of appeal from the lower court’s decision on August 21, 2019. The court’s 
decision focused on the issue of whether the Secretary of H.H.S, had the authority to regulate drug 
advertising under the Social Security Act . 
(https://1.next.westlaw.com/Document/IB2CD0786C54411E99B14F2EE541CF11A/View/FullText.htm
l?listSource=RelatedInfo&list=NegativeCitingReferoritences&rank=0&originationContext=docHeader
&transitionType=NegativeTreatment&contextData=%28sc.Search%290). See also Steven Woloshin, Ask 
Whether A Drug Works Before Worrying About What It Costs, L.A, Times (July 26, 2019). 
 2. Press Release, AMA Adopts Policy Aimed to Bolster Transparency of Prescription Costs (June 
17, 2018), https://www.ama-assn.org/ama-adopts-policy-aimed-bolster-transparency-prescription-costs#. 
 3. Robert Pear, Would Requiring Ads For Drugs to Cite Costs Really Lower the Prices?, N. Y. 
TIMES (May 19, 2018), https://www.nytimes.com/2018/05/19/us/politics/drug-prices-ads.html; Jace B. 
Garrett et al., Consumer Responses to Price Disclosure in Direct-to-Consumer Pharmaceutical 
Advertising, 179 JAMA INTERNAL MED. 435 (2019). 
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concerns about a high-price for a drug.4 The significance of drug prices to 
consumers is further complicated both by the “market-distorting effects of third-
party payors”5 and the requirement for consultation with and prescription by a 
licensed physician whose decisions may also be impacted by third-party payors, 
but is not necessarily affected by the list prices of drugs. However, the thesis of 
this article is not that disclosing prices in DTC ads is a bad idea, but that 
providing consumers with information about how effective advertised drugs are 
likely to be for them would provide information that patients need regardless of 
their insurance or financial status. Additionally, it would likely have a greater 
impact on the pharmaceutical marketplace. If the problem with DTC ads, as the 
AMA stated in its proposal to require price disclosures, is that “patients pressure 
physicians to prescribe certain medications that cost more than lower-cost 
alternatives and are not necessarily as efficacious,”6 then requiring DTC ads to 
provide consumers with clear information about the effectiveness of the 
advertised drug would be an even more powerful solution. 
There is a growing awareness of the need to require disclosures of expected 
effectiveness in pharmaceutical DTC marketing. Currently, consumers are told 
about the general condition for which a drug is used: e.g. “Drug X is approved 
for the treatment of major depressive disorder,” or “Drug X has been proven 
effective for the treatment of depression”; but rarely are consumers given 
information about the average benefit achieved in clinical trials or in post-market 
studies. This is a particular problem in DTC advertising for prescription 
pharmaceuticals. An article, in The New York Times by Elizabeth Rosen, 
highlighted the problem of DTC ads that are likely to mislead consumers about 
a drug’s effectiveness and provided this example: “Another ad promoted Jublia, 
a new topical drug for toenail fungus that costs thousands of dollars for a full 
course of treatment. Complete cure rates in studies—under 20 percent after 48 
weeks of use—aren’t mentioned in the ads.”7 
While the problem is becoming well known, as the New York Times article 
illustrates, the FDA regulation of pharmaceutical marketing is significantly 
constrained by the First Amendment’s protection of commercial speech, which 
would almost certainly make a ban on DTC pharmaceutical ads 
unconstitutional.8 This article provides an approach to FDA regulation of DTC 
ads that would address the problem within the limits of the First Amendment’s 
protection for commercial speech and provide patients with the information they 
 
 4. Garrett et al., supra note 3, at 436. 
 5. CMS, supra note 1 at 52,790. 
 6. Press Release, supra note 2. 
 7. Elizabeth Rosen, Ask Your Doctor If This Ad Is Right for You, N.Y. TIMES (Feb. 27, 2016), 
https://www.nytimes.com/2016/02/28/sunday-review/ask-your-doctor-if-this-ad-is-right-for-you.html. 
 8. Sorrell v. IMS Health Inc., 564 U.S. 552, 544 (2011). 
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need most to sort through the glossy promotional advertisements created by 
pharmaceutical companies and their ad agencies.  
The issue of advertising drugs to consumers is just one aspect, albeit the 
most visible, of the general problem of pharmaceutical companies’ efforts to sell 
drugs without substantive support for the choices to which their marketing efforts 
are directed. For example, in 2005 The New York Times published an article 
entitled Gimme an Rx! Cheerleaders Pep Up Drug Sales.9 The article 
documented the efforts of pharmaceutical companies to recruit college 
cheerleaders for pharmaceutical sales positions. Why do Pharmaceutical 
companies recruit cheerleaders to market their drugs to physicians? The reason 
why is not, in my opinion, the obvious one. I believe that the real reason for 
hiring energetic and attractive salespeople who may not have a background in 
science10 is because for most drugs, the pharmaceutical companies do not have 
the data that would make choosing their drug a rational, rather than subjective or 
arbitrary, choice. The strategies used to market drugs to doctors and to consumers 
are largely driven by the lack of more complete data. So while attractive, high 
energy sales representatives with rolling bags head towards doctors’ offices, 
butterflies (Lunesta),11 weird, letter-shaped cats and dogs (Belsomra),12 serene 
patients with bi-polar depression (Latuda),13 and attractive, apparently sexually 
satisfied women lounging on beds (Viagra)14 fill the TV screens of America’s 
households. What’s the message? “If you have this problem, we can fix it.” Or, 
rather, “If you have the indication for which the FDA approved this drug, this is 
an effective treatment that is the best choice for you.” My proposed solution is 
that the FDA use its power to regulate drug labeling15 to require that DTC ads 
contain a concise and clear statement of the expected benefit provided by the 
drug. The required disclosure would be based on data from trials that supported 
the FDA approval of the advertised indication or post-marketing studies that have 
been reviewed by the FDA, in a format that follows the recommendations of the 
 
 9. Stephanie Saul, Gimme an Rx! Cheerleaders Pep up Drug Sales, N.Y. TIMES (Nov. 28, 2005), 
http://www.nytimes.com/2005/11/28/business/gimme-an-rx-cheerleaders-pep-up-drug-sales.html?_r=0.  
 10. Id. Dr. Dan Foster, a West Virginia legislator, introduced a bill that would have required 
pharmaceutical reps to have a science degree, but the bill was not enacted.  
 11. Haydenriggsnz, LUNESTA® (Eszopiclone) Sleeping Pill Commercial Ad—USA (Real One), 
YOUTUBE (Feb. 3, 2012), https://www.youtube.com/watch?v=vu0rXFhsM8w (last visited Dec. 11, 2019). 
 12. Belsomra TV Commercial, ‘Cats and Dogs,’ ISPOT.TV (2015), 
https://www.ispot.tv/ad/7UYo/belsomra-cats-and-dogs. 
 13. Latuda TV Commercial, ‘Maya’s Story,’ ISPOT.TV (2016), 
https://www.ispot.tv/ad/ANW0/latuda-mayas-story.  
 14. Viagra TV Commercial, ‘Save 50 Percent,’ ISPOT.TV (2017), 
https://www.ispot.tv/ad/A82U/viagra-save-50-percent.  
 15. See Prescription-Drug Advertisements, 21 C.F.R. § 202.1(e) (2018). 
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FDA’s just-released Draft Guidance for “Presenting Quantitative Efficacy and 
Risk Information” in DTC advertising.16 
In Part I of this Article I illustrate the problem of misleading DTC ads with 
the advertisements for two widely advertised drugs. In analyzing the ad content, 
my focus is on whether the images and the language of the ad could reasonably 
be construed to imply that the drug is likely to provide a significant benefit to 
most patients. I also discuss whether the ad suggests that the drug would be the 
best choice among all available drugs for that condition. I use the data that 
supported the FDA’s decision to approve the drugs to address the extent to which 
patients are actually likely to experience significant benefits from use of the drug. 
I compare the data for the advertised drug with one other drug approved for its 
indication to determine whether there is a rational, objective reason to prefer the 
advertised drugs with implied claims of superiority. After examining the ads and 
the actual data for those drugs, in Part II of this Article I briefly discuss the 
concept of “pragmatic implications,”17 which is an important concept in 
marketing and central to understanding the issue of whether DTC advertising is 
generally misleading (and therefore subject to some governmental regulation 
under the Central Hudson test for commercial speech).18 There is a plausible 
basis for finding each of these commercials to be misleading, as would be the 
case with most DTC ads. In Part III, I conclude by analyzing the application of 
Central Hudson to DTC ads to support my argument that the FDA can and should 
require a concise summary statement of expected benefit in DTC ads.19 
I.  THE PRODUCTS, THE COMMERCIALS, THE IMAGES, AND THE DATA. 
The two drug commercials analyzed in detail are Latuda’s commercial 
promoting the use of the drug for bi-polar depression20 and Belsomra’s ad 
promoting its use for insomnia.21 The images in both ads present a similar story 
to the potential consumer. In both commercials the images at the beginning show 
a person who has the indication or medical condition targeted by the drug. In the 
Latuda commercial we see a woman who talks about being sad and looks sad. 
The background narrator says, “Latuda is FDA approved to treat Bipolar 
Depression, which is different from other forms of depression.” After the on-
screen actress portraying a patient meets with her doctor, she is out walking, 
playing with her dog, and smiling. The story from the images is clear––Latuda 
 
 16. U.S. FDA, Draft Guidance: Presenting Quantitative Efficacy and Risk Information in Direct-to-
Consumer Promotional Labeling and Advertisements Guidance for Industry (2018). 
 17. See Richard J. Harris, Comprehension of Pragmatic Implications in Advertising, 62 J. APPLIED 
PSYCHOL. 603 (1977). 
 18. Cent. Hudson Gas & Elec. Corp. v. Pub. Serv. Comm’n. of N.Y., 447 U.S. 557, 564 (1980).  
 19. See supra note 13. 
 20. Belsomra TV Commercial, supra note 12. 
 21. Id. 
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takes away your depression and helps you feel good. The images provide the 
context for the other key language in the Latuda commercial: “In clinical studies, 
once-a-day Latuda was proven effective for people with bipolar depression.” The 
message is clear: If you suffer from this condition (bipolar depression), you will 
get better if you take Latuda. There is no “perhaps you will” or “there is a 50/50 
chance you will.” Furthermore, if a viewer follows the standard advice to “ask 
your doctor” about Latuda, the full prescribing information for the drug upon 
which the doctor may rely for information shows that patients receiving Latuda 
as a monotherapy (the only drug for that condition) in the pivotal clinical trial 
achieved about a median 4.6 point greater improvement in the MADRS 
depression rating scale compared with patients receiving a placebo. This 4.6 
point difference is from a median baseline score of just over 30 points, where a 
score “greater than 30 or 35 on the MADRS indicates severe depression, while a 
score of 10 or below indicates remission.”22 Because Latuda is unlikely to be the 
only drug used by many patients with bipolar disorder and depression, the study 
also provided results for patients given either Latuda or a placebo in addition to 
either Lithium or Valproate, two commonly prescribed drugs for bipolar 
disorder.23 Those results showed a smaller difference between the patients 
receiving Latuda and those receiving a placebo. However, even though a 15 point 
or greater median improvement (or the slightly smaller improvement achieved 
by the placebo group) is certainly meaningful, that data––the only data on the 
prescribing information––does not inform the physician (or the patient) how 
likely the patient is to achieve remission (a score below 10 on the MADRS scale 
used in the trial). If the image in the commercial strongly suggests that the post-
treatment patient is now free from depression that is unlikely to be true. The only 
way to know how likely patients prescribed Latuda are to be free from depression 
is to go beyond the label or prescribing information and look into the NIH’s 
PubMed database to find the studies that supported Latuda’s approval. Here is 
additional data from the trials that supported the approval of Latuda (lurasidone) 
for bipolar depression, but were not in the prescribing information: 
A significantly greater proportion of subjects met a priori response 
criteria after 6 weeks of treatment with lurasidone 20–60 mg (53%; 
p<0.001 [number needed to treat=5]) and lurasidone 80–120 mg 
(51%; p<0.001 [number needed to treat=5]) compared with placebo 
(30%). 
The proportion of subjects achieving remission at end-point was 
significantly greater in the lurasidone 20–60 mg group (42%; p=0.001 
[number needed to treat=6]) and the lurasidone 80–120 mg group 
 
 22. Christina Cusin et al., Handbook of Clinical Rating Scales and Assessment in Psychiatry and 
Mental Health (chapter 2) 13 (Lee Blair & Mark Blais, eds., 2009). 
 23. Mark Watanabe, Pharmacotherapy for Bipolar Disorder: An Updated Review, 32 U.S. 
PHARMACIST 26–32 (2007), https://www.uspharmacist.com/article/pharmacotherapy-for-bipolar-
disorder.  
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(40%; p=0.004 [number needed to treat=7]) compared with the 
placebo group (25%).24 
While the images of a smiling, active woman and the words “proven 
effective” suggest more than a roughly 50% likelihood of clinical improvement 
and a 42% likelihood of at least temporary complete relief, the data supporting 
Latuda’s approval shows no more than that 50% likelihood of clinical 
improvement. And the ad does not tell the viewer anything about the 
effectiveness of Latuda as compared to other drugs for the same indication.  
Symbyax is another drug approved for the treatment of bipolar depression 
and as such, the clinical trial data associated with Symbyax can be compared to 
that for Latuda. The comparable data for Symbyax as in bipolar depression is 
shown below:  
The response rate . . . for the placebo group . . . [was] 30.4%[data on 
olanzapine only arm omitted]…The response rate for the [Symbyax] 
olanzapine-fluoxetine group was 56.1%… which was significantly 
higher than that for the placebo … 
The remission rate for …the placebo group … [was] 24.5%. . .The 
remission rate for the olanzapine-fluoxetine group was 48.8% …25  
It is important to note when looking at the two data sets that no definitive 
conclusion can be reached in terms of the relative effectiveness of Latuda and 
Symbyax based on the results achieved in these separately run trials, despite the 
better numbers for Symbyax in its study compared with the results for Latuda in 
its study. The results of different trials at different times by different investigators 
at different sites (and countries) cannot be directly compared. Furthermore, the 
safety issues of each of the drugs does not support any meaningful comparison 
based on the top-line results simply measuring the effectiveness of the two drugs. 
A clear answer to the superiority of competing drugs can only be answered by a 
well-designed head-to-head study.26 However, any commercial that implies that 
most patients who take Latuda will achieve remission, or that the great majority 
of patients achieve meaningful relief, or even that Latuda is THE appropriate 
choice for patients with bipolar depression is misleading.  
Does the “ask your doctor” clause provide an effective remedy for any 
misleading impression created by the advertisement because that misleading 
impression would be corrected by the doctor? No, because the labeling 
information summarizing the clinical effectiveness data for Latuda only shows 
 
 24. Antony Loebel et al., Lurasidone Monotherapy in the Treatment of Bipolar I Depression: A 
Randomized, Double-Blind, Placebo-Controlled Study, 171 AM. J. PSYCHIATRY 160, 160–68 (2014). 
 25. Mauricio Tohen et al., Efficacy of Olanzapine And Olanzapine-Fluoxetine Combination in the 
Treatment of Bipolar I Depression, 60 ARCHIVES GEN. PSYCHIATRY 1079–88 (2003). 
 26. Robert A. Bohrer, The Need For Publicly Funded Trials to Get Unbiased Comparative 
Effectiveness Data, HEALTH AFF.: HEALTH ’POL’Y LAB (Feb . 20, 2015), 
http://healthaffairs/blog/2015/02/20/the-need-for-publicly-funded-trials-to-get-unbiased-comparative-
effectiveness-data/.  
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changes in the median difference in depression score for the patients receiving 
the drug. This is compared with the changes in depression score for the patients 
receiving the placebo, but contains nothing about the percentage of patients who 
achieved remission. The real answer to one of the most important questions that 
a patient might want ask a doctor before choosing a drug––”How likely am I to 
be helped?”––is not answered by the label. The doctor would have to search 
through the literature to find the answer and even then the doctor would be unable 
to answer the question of how Latuda’s effectiveness compares to that of other 
drugs that treat the same problem.  
Imagine that same commercial with the clear printed message and 
background narration stating that, “Approximately 53% of patients in the clinical 
trial achieved a significant benefit from Latuda compared with 30% of patients 
receiving a pill with no active ingredients. About 40% of patients receiving 
Latuda achieved remission or relief from depression compared with 25% of 
patients who took a pill with no active ingredients. No evidence suggests that 
Latuda works better than other drugs for bipolar depression.” That ad would 
almost certainly be less effective in persuading patients to “ask their doctor” if 
Latuda is the right drug for them and may not be worth broadcasting at all. 
If the analysis of Latuda’s data has not put you to sleep yet, Belsomra, a 
drug designed to treat insomnia, is marketed to do just that. The visual images 
generated for the ad are fascinating. Zoomorphic furry letters spelling “sleep” 
and “wake” romp around the bedroom setting for the opening of the Belsomra 
commercial.27 Don Draper would be rolling on the floor laughing.28 Beyond the 
complete surrealist fantasy of animated furry letters representing sleep and wake 
messages, the images again imply more or less complete effectiveness. The 
woman at the beginning of the ad looks tired and is searching for sleep. Having 
taken Belsomra, she finally is seen sleeping soundly (and somehow a male has 
magically appeared in her bed to suggest some additional benefit to the drug). 
The story from the images is clear: if you suffer from insomnia and take 
Belsomra you will start sleeping well and feeling rested, and your love life might 
benefit as well.  
The key language for Belsomra is that it can “turn down wake messages” 
by “targeting and inhibiting the action of orexin, a neurotransmitter that plays a 
central role in sending wake messages. Only Belsomra works this way.” This 
central verbal message of the Belsomra ad points to its first-in-class mechanism 
of action––”Only Belsomra works this way.” It is subtler than the “proven 
effective” message of the Latuda ad, but it is hard to infer any other motivation 
for featuring its unique mechanism or action other than the suggestion that this 
new mechanism of action provides greater effectiveness than the older classes of 
 
 27. Belsomra TV Commercial, supra note 12. 
 28. Don Draper was the character portrayed by Jon Hamm in Mad Men, the television drama about 
the advertising agency world of the 1960s.  Mad Men (AMC televison 2007–2015). 
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drugs that work on other pathways. It is reasonable to conclude that the purpose 
of including it in the ad is that market research indicated that including that 
information does suggest superiority. So, is it superior? And if it is, how effective 
is it?  
There are other non-benzodiazepine drugs for insomnia to which 
Belsomra’s effectiveness can be compared, such as Lunesta (eszopiclone).29 Is 
there evidence that supports the suggestion that by working this way Belsomra 
is more effective than Lunesta or other non-benzodiazapene drugs for insomnia? 
Shown below is the data from Table 3 of the Belsomra prescribing information–
–the polysomnographic measurement of “time to sleep onset” from two studies:30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
While there is also data on “sleep maintenance” in the Belsomra prescribing 
information, for purposes of comparisons to Lunesta it is reasonable to use this 
top line primary efficacy measure––8 to 10 minutes less time to fall asleep as 
measured at 30 days. To be generous in this context, I will ignore the 0 difference 
compared to placebo at month 3 in study 2. 
How does data for Lunesta, which does not target orexin but does have 
exactly the same indication, compare? Here, the data is not in the label but can 
be found in a journal article reporting on one of the clinical trials relied on for 
 
 29. Gregory M. Asnis, Thomas Manju and Margaret A. Henderson. Pharmacotherapy Treatment 
Options For Insomnia: A Primer For Clinicians, 17 int. j. of molecular sciences 50 (2015) 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4730295/pdf/ijms-17-00050.pdf. 
 30. Merck, Belsomra Full Prescribing Information, 
https://www.merck.com/product/usa/pi_circulars/b/belsomra/belsomra_pi.pdf (last visited July 11, 2018). 
  
2019] REQUIRED DISCLOSURES 217 
approval.31 All the label states is that the drug was more effective than the 
placebo on these measures. It is fairly clear that following the ad’s 
recommendation to “ask your doctor” would not be likely to provide a patient 
with any information about how well the competing drug actually works, as the 
doctor would be unable to know from the prescribing information. Here is the 
data from the actual research article:32 
Table 2. Summary of PSG Sleep Efficacy Results 
Measure  Baseline Night 1 Night 15 Night 29 Double-
blind 
Average 
 Mean 
(SD) 
Median Mean 
(SD) 
Median Mean 
(SD) 
Median Mean 
(SD) 
Median Mean 
(SD) 
Median 
LPS 
(min) 
PBO 38.4 
(35.1) 
27.5 35.2 
(28) 
28.6 34.0 (28) 27.0 30.2  
(28.2) 
20.5 33(22.6) 29.0 
ESZ 
2mg 
39.5 
(36.1) 
30 21.4 
(27.6) 
11.8 21.9 
(21.1) 
15.5 24 
(35.8) 
12.9 23 
(24.9) 
15.0 
ESZ 
3mg 
42.8 
(41.6) 
30.1 17.5 
(20.2) 
12.3 19.5(19.6) 13.8 18.1 
(26.1) 
11.5 18 
(15.7) 
13.1 
 
The endpoint shown here is “LPS,” defined by the investigators “as the time 
from lights out to the first 20 consecutive epochs (10 consecutive minutes) of 
sleep.” For the purpose of this analysis, LPS is a fairly close comparator to the 
“time to sleep onset” measured for Belsomra. The data on this difference in “the 
time to sleep” for subjects who received the test drug rather than placebo was 
between 10 minutes less time to fall asleep for Belsomra at 30 days compared to 
7 to 8.5 minutes less for Lunesta patients at 29 days. However, to further 
emphasize the point about not using the data from a study of one drug to draw a 
conclusion about its comparative effectiveness to another drug,33 the other 
endpoints in the Lunesta study were different from the endpoints used for 
Belsomra. It is not possible to conclude which drug is more effective (or safer) 
from these disparate studies, and any implicit message that either drug is the drug 
of choice for patients with insomnia is obviously not supported by the data, nor 
would heeding the ad’s suggestion to “ask your doctor” likely provide the 
answer. Although the prescribing information for Belsomra does contain some 
effectiveness data about Belsomra, the prescribing information for Lunesta does 
not. 
 
 31. Gary K. Zammit et al., Efficacy and Safety of Eszopiclone Across 6-Weeks of Treatment for 
Primary Insomnia, 20 CURRENT MED. RES. & OPINION 1979–1991 (2004). 
 32. Id. 
 33. See Bohrer, supra note 26. 
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II: PRAGMATIC IMPLICATIONS AS A MARKETING STRATEGY 
The phenomenon of pragmatic implications has been well-studied and 
repeatedly demonstrated in marketing literature.34 Searleman and Carter defined 
‘pragmatic implications’ as “statements that lead a person to believe something 
that is neither explicitly stated nor necessarily implied.”35 Advertisers rely on the 
general beliefs of consumers to interact with the content of an advertisement to 
create consumer perceptions about the product without any direct assertions 
about the product’s effectiveness or performance. Such perceptions are 
‘pragmatically implied’ and ads designed to create such factually unsupported 
pragmatic implications are misleading.36 While an advertisement that contains a 
false pragmatic implication can be tested by researchers, the goal of every 
marketer is to persuade the consumer that the product advertised is the best 
choice for a particular function.  
Having a doctor as a required intermediary would seem to provide a 
corrective function for unsupported implications. However, it is clear that in 
many cases the doctor is unlikely to have the information needed to correct the 
impressions created by the ad. For example, the prescribing information for 
Lunesta (a competitor of Belsomra) and for Symbyax (a competitor of Latuda) 
contain no precise quantitative or comparative data for effectiveness. Instead, the 
only statement made in the prescribing information for those competitor drugs is 
that the drug in question was more effective than the placebo control in clinical 
trials prior to FDA approval. Furthermore, the prescribing information for the 
advertised drugs does not contain any comparative effectiveness data to inform 
the doctor.  
There have been numerous studies on the effect of direct-to-consumer 
advertising on healthcare. There is strong evidence that direct-to-consumer 
advertising increases the number of doctor’s visits.37 There is also evidence that 
the number of prescriptions for an advertised indication increases.38 Although an 
FDA survey found that 58% of physicians “agreed strongly that DTC ads make 
the drugs seem better than they really are,” there is no consensus about the 
percentage of prescriptions that result for the advertised product. The FDA 
finding concerning physicians’ views of patients’ perceptions created by DTC 
ads strongly supports the position taken here, which is that DTC ads are 
 
 34. See e.g. Alan Searleman & Helen Carter, The Effectiveness of Different Types of Pragmatic 
Implications Found in Commercials to Mislead Subjects, 2 APPLIED COGNITIVE PSYCHOL . 265 (1988); 
Harris, supra note 17.  
 35. Id. 
 36. Harris, supra note 17. 
 37. E.g. Toshiaki Iizuka & Ginger Zhe Jin, The Effect of Prescription Drug Advertising on Doctor 
Visits, 14 J. ECON. & MGMT STRATEGY 701 (2005). 
 38. Richard L. Kravitz et al., Influence of Patients’ Requests for Direct-to-Consumer Advertised 
Antidepressants: A Randomized Controlled Trial, 293 JAMA 1995 (2005). 
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implicitly misleading. The pragmatic implication of superior effectiveness is 
pharmaceutical marketers’ tool of choice: DTC ads are used because they 
succeed. The ads increase sales of the advertised drugs, almost always without 
any support for the conclusion that the advertised drugs are in any way better 
than the other drugs that might be used. 
III: A REQUIRED CONCISE STATEMENT OF BENEFIT AND CENTRAL HUDSON 
The regulatory remedy for the pragmatic, misleading implications of direct-
to-consumer advertising proposed here is a concise statement of the average 
benefit that patients taking the advertised drug receive. For example, in the 
Belsomra commercial, just before the required summary of potential adverse 
effects, the voice actor narrating the ad would be required to say, “In clinical 
studies, patients taking Belsomra for insomnia fell asleep 8 to 10 minutes more 
quickly than patients taking a placebo.” That is, of course, what the 
pharmaceutical company’s own studies showed. And, like any other 
pharmaceutical ad or part of a pharmaceutical ad, the accuracy of the concise 
statement of average benefit could be reviewed by the FDA and any inaccurate 
or misleading statements would be subject to regulatory action or sanction.39 
However, since pharmaceutical marketing is commercial speech,40 the question 
presented here is whether or not an FDA-required concise statement of average 
benefit would be constitutional if analyzed under Central Hudson.41 
In Central Hudson, the Supreme Court held that under the First 
Amendment, governmental regulation of commercial speech is subject to a three-
part test: 
For commercial speech to come within that provision [i.e. be protected 
by the First Amendment], it at least must concern lawful activity and 
not be misleading. Next, we ask whether the asserted governmental 
interest is substantial. If both inquiries yield positive answers, we must 
determine whether the regulation directly advances the governmental 
interest asserted, and whether it is not more extensive than is necessary 
to serve that interest.42  
Applying Central Hudson to direct-to-consumer pharmaceutical ads, the 
required disclaimers would be upheld if the ads are inherently misleading in 
suggesting either that the drugs are more effective than their data shows, or that 
 
 39. E.g., Meena Ramachandra & Melinda McLawhorn, Orexigen Therapeutics, Inc. (Contrave) 
Untitled Letter 5/18/2017, U.S . Food & Drug Administration, 
https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/
WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/ucm560127.htm (last visited 
June 1, 2017) (letter of Meena Ramachandra (FDA) to Stacy Hennings, Sr. Director, Regulatory Affairs 
Advertising & Promotions Orexigen Therapeutics, Inc.).  
 40. See Sorrell v. IMS Health Inc., 564 U.S. 552, 557 (2011). 
 41. Cent. Hudson Gas & Elec. Corp. v. Pub. Serv. Comm’n. of N.Y., 447 U.S. at 564. 
 42. Id. 
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the advertised drug is the best drug for the advertised indication. Even the 
language “proven effective” of the Latuda commercial43 would be likely to 
mislead the ordinary television viewer even though the word “effective” has a 
specialized meaning in the context of the FDA.44 To the average viewer of a 
television advertisement the word “effective” is most likely to have its ordinary 
English language meaning, which is “[s]uccessful in producing a desired or 
intended result.”45 
However, it is unlikely that a court facing a challenge to the regulation 
would stop there. If the advertisement is not overtly or expressly misleading, then 
it is likely that commercial speech protection would apply and that it is necessary 
to proceed to the remaining steps of the Central Hudson analysis. If the 
governmental interest is to counteract the potential implication of superior or 
even significant effectiveness for most patients, then a concise statement of the 
actual effectiveness of the drug would directly advance that governmental 
interest. That leads to the final step in Central Hudson: Would a required 
disclaimer be more extensive than is necessary to counteract the potentially 
misleading nature of the ad? It is difficult to imagine a governmental regulation 
that would be less extensive and accomplish that goal. In the recent First 
Amendment decision by the Supreme Court, National Institute of Family Life 
Advocates v. Becerra,46 a case striking down required disclosures in the very 
different context of religious organizations and abortions, Justice Thomas’s 
majority opinion went on to affirm that “we do not question the legality of health 
and safety warnings long considered permissible, or purely factual and 
uncontroversial disclosures about commercial products.”47 The required 
disclaimers suggested here are both health directed and purely factual and 
uncontroversial––they are the advertisers’ own data used in support of the 
approval of their products. 
Would a required disclaimer of any superiority to other drugs for that 
indication (in the absence of FDA-reviewed comparative effectiveness studies) 
be less extensive or objectionable to the pharmaceutical industry? It is doubtful, 
as advertising a product and stating that it is no better than other products for that 
function defeats the purpose of advertising at all. And that is the precisely the 
point: A concise statement of the effectiveness of DTC-advertised drugs would 
go a long way towards curing the problems that DTC advertising creates. With 
the current clamor about pharmaceutical prices and prescription drug advertising, 
now is the time for the FDA to take action and require pharmaceutical companies 
 
 43. Latuda TV Commerical, supra note 13. 
 44. Adequate and Well-Controlled Studies, 21 C.F.R. § 314.126 (2018). 
 45. Effective, OXFORD LIVING DICTIONARIES, https://en.oxforddictionaries.com/definition/effective.  
 46. Nat’l. Inst. of Family Life Advocates v. Becerra, 138 S.Ct. 2361(2018). 
 47. Id. at 2376. 
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to provide patients with a concise statement of how effective their drugs have 
been proven to be. 
 
